Acute, subacute and chronic aspergillosis remain major threats for human health, especially in immuno-
suppressed hosts and patients with underlying structural lung disease. Despite significant strives, only
three classes of molecules are currently used in clinical practice. The emerging azole resistance threats to
devitalize the activity of the most commonly used drugs for that disease, the triazoles. In my lecture, I will
summarize the unmet clinical needs of current antifungal therapy for aspergillosis, discuss the emerging
pipeline and agents belonging to new molecular classes, the challenges inherent to antifungal drug discovery
and development, and offer some perspectives for the future.